Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Dae Young Lee, Ju-Hyun Kim, Hyun Joo Shim, Hyeon-Uk Jeong & Hye Suk Lee. (2018) Absorption, metabolism, and excretion of [14C]evogliptin tartrate in male rats and dogs. Journal of Toxicology and Environmental Health, Part A 81:11, pages 453-464.
Read now
Read now
Articles from other publishers (21)
Pankaj M. Kharabe, Prasad P. Jumade, Pravin N. Khatale, Parimal P. Katolkar, Santosh R. Butle, Mahendra D. Kshirsagar, Vishal V. Pendharkar, Amol V. Sawale & Kalyani S. Choudhari. (2023) Reverse Phase, Ion Exchange, HILIC and Mix-Mode Chromatography for the Determination of Metformin and Evogliptin in Human Plasma and Pharmaceutical Formulations. Talanta Open, pages 100274.
Crossref
Crossref
Deepanti Gajjar & Dimalkumar S. Shah. (2023) Development of stability indicating liquid chromatographic method for estimation of novel anti‐diabetic drug Evogliptin. SEPARATION SCIENCE PLUS 6:12.
Crossref
Crossref
Pyung Goo Cho, Jun Ho Jang, Sukjin Ko, Dong Ah Shin, Seungsoo Chung & Min Cheol Chang. (2023) The Effect of Evogliptin Tartrate on Controlling Inflammatory Pain. Biomedicines 11:11, pages 2990.
Crossref
Crossref
Khushbu Patel, Ujashkumar A. Shah & C. N. Patel. (2023) Box–Behnken design-assisted optimization of RP-HPLC method for the estimation of evogliptin tartrate by analytical quality by design. Future Journal of Pharmaceutical Sciences 9:1.
Crossref
Crossref
Byungwook Kim, Dha Woon Im, Heejae Won, Jung Sunwoo, Seung Seok Han, Hajeong Lee, Dong Ki Kim, Kook‐Hwan Oh, Kwon Wook Joo, Yon Su Kim, Joo‐Youn Cho, SeungHwan Lee, Jaeseong Oh, In‐Jin Jang & Yong Chul Kim. (2023) Effect of haemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin. Diabetes, Obesity and Metabolism 25:6, pages 1769-1776.
Crossref
Crossref
Kunika Saini, Smriti Sharma & Yousuf Khan. (2023) DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature. Frontiers in Molecular Biosciences 10.
Crossref
Crossref
Surya Prakash Gupta & Sachin Singh. (2023) RP-HPLC Based Stability Indicating Assay of Evogliptin and Metformin: Development and Validation of the Analytical Method. International Journal of Pharmaceutical Sciences and Nanotechnology(IJPSN) 16:2, pages 6438-6444.
Crossref
Crossref
Yu‐Ping He, Rui Quan, Xing‐Zi Li, Jieping Zhu & Hua Wu. (2023) Asymmetric Construction of α,α‐Disubstituted Piperazinones Enabled by Benzilic Amide Rearrangement. Angewandte Chemie International Edition 62:18.
Crossref
Crossref
Yu‐Ping He, Rui Quan, Xing‐Zi Li, Jieping Zhu & Hua Wu. (2023) Asymmetric Construction of α,α‐Disubstituted Piperazinones Enabled by Benzilic Amide Rearrangement. Angewandte Chemie 135:18.
Crossref
Crossref
Trong Kha Pham, To Hoai T. Nguyen, Joo Mi Yi, Gwang Sil Kim, Hyeong Rok Yun, Hyoung Kyu Kim & Jong Chul Won. (2023) Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db/db mice. Experimental & Molecular Medicine 55:4, pages 767-778.
Crossref
Crossref
Carlos T. Nieto, Alejandro Manchado, Leland Belda, David Diez & Narciso M. Garrido. (2023) 2-Phenethylamines in Medicinal Chemistry: A Review. Molecules 28:2, pages 855.
Crossref
Crossref
R. Pelluri, S. Kongara, V. R. Nagasubramanian, S. Mahadevan & J. Chimakurthy. (2023) Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes. Journal of Endocrinological Investigation 46:5, pages 855-867.
Crossref
Crossref
Shubham Kumar, Anu Mittal & Amit Mittal. (2021) A review upon medicinal perspective and designing rationale of DPP-4 inhibitors. Bioorganic & Medicinal Chemistry 46, pages 116354.
Crossref
Crossref
Hojin Oh, Hai Duc Nguyen, In Mo Yoon & Min-Sun Kim. (2021) Efficacy and Tolerability of Evogliptin in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis with Bayesian Inference Through a Quality-management System. Clinical Therapeutics 43:8, pages 1336-1355.
Crossref
Crossref
Mi-Jin Kim, Na-young Kim, Yun-A JungSeunghyeong LeeGwon-Soo JungJung-Guk KimIn-Kyu LeeSungwoo LeeYeon-Kyung Choi & Keun-Gyu Park. (2020) Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice. Diabetes & Metabolism Journal 44:1, pages 186.
Crossref
Crossref
Zheng WangHansu ParkEun Ju Bae. (2019) Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study. The Korean Journal of Physiology & Pharmacology 23:6, pages 459.
Crossref
Crossref
Anna A. Mosikian, Alina Y. Babenko, Yulia A. Sevastyanova, Roman V. Drai & Evgenij V. Shlyakhto. (2018) Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population. Diabetes mellitus 21:5, pages 333-343.
Crossref
Crossref
Xiaoxuan Li, Xuefei Huang, Chongfei Bai, Dalian Qin, Shousong Cao, Qibing Mei, Yun Ye & Jianming Wu. (2018) Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology 9.
Crossref
Crossref
Poonam Giri, Shuchi Joshi & Nuggehally R Srinivas. (2018) Regression modeling strategy for prediction of AUC of evogliptin, a novel dipeptidyl peptidase IV inhibitor in humans, using single dose PK data. International Journal of Pharmacokinetics 3:1, pages 23-38.
Crossref
Crossref
Juri Park, Sung Woo Park, Kun Ho Yoon, Sung Rae Kim, Kyu Jeung Ahn, Jae Hyuk Lee, Ji Oh Mok, Choon Hee Chung, Kyung Ah Han, Gwan Pyo Koh, Jun Goo Kang, Chang Beom Lee, Seong Hwan Kim, Na Young Kwon & Doo Man Kim. (2017) Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise. Diabetes, Obesity and Metabolism 19:12, pages 1681-1687.
Crossref
Crossref
T. Biftu & R. SinhaRoy. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
512
555
.